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A B S T R A C T
Objective: To determine whether fat mass and obesity-associated gene polymorphisms rs9939609 T>A
and rs8050136 A>C or their haplotypes inﬂuence anthropometric and metabolic variables in recently
postmenopausal women receiving hormone therapy.
Study design: In this randomized crossover study carried out in a university clinic, 86 postmenopausal
women consulting for symptoms of estrogen deﬁciency were genotyped by real-time polymerase chain
reaction for single nucleotide polymorphisms rs9939609 T>A and rs8050136 A>C of the fat mass and
obesity-associated gene. Haplotypes were constructed from the combination of polymorphisms
rs9939609 and rs8050136, and their frequencies were inferred using the PHASE 2.1.1 program.
Participants were clinically evaluated before and after 6 months of hormone therapy to determine body
mass index (current kg/m2) and waist circumference, blood pressure, lipid proﬁle (total cholesterol, HDL
cholesterol and triglycerides) plasma glucose (oral glucose tolerance test), and insulin. Blood samples
were also drawn for ultra sensitive C reactive protein. The lipid accumulation product index was
calculated as (waist [cm] – 58)  triglyceride concentration (mmol/L). Non-normally distributed
parameters were log10 transformed before statistical analysis. Measurements at baseline and at follow-
up were compared with ANOVA for repeated measures. Data were considered signiﬁcant at P < 0.05.
Results: In women with the homozygous polymorphic AA genotype of the single nucleotide
polymorphisms rs9939609 and the wild AA genotype of the single nucleotide polymorphisms
rs8050136, lipid accumulation product index and ultra sensitive C reactive protein were higher before
hormone therapy in comparison with women with other genotypes from the same single nucleotide
polymorphisms group. There was no worsening of any of the anthropometric or metabolic variables, and
lipid accumulation product index improved slightly after hormone therapy in SNP rs9939609 (P = 0.03)
and haplotype AAAA. No changes were observed after hormone therapy in SNP rs8050136.
Conclusions: The presence of fat mass and obesity-associated gene risk variants in healthy early
postmenopausal women does not adversely affect their response to hormone therapy.
 2012 Elsevier Ireland Ltd. 
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In the postmenopausal period, women experience an expo-
nential increase in the risk of cardiovascular disease, the leading
cause of death in this population [1]. During the reproductive
years, endogenous estrogens exert beneﬁcial effects on endothe-
lial function and lipids, and the estrogen deﬁciency that occurs
after the menopause has been related to a worsening in the clinical§ This study was conducted at Hospital de Clı´nicas de Porto Alegre (HCPA), Porto
Alegre, Brazil.
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Open access under the Elsevier OA license.and metabolic proﬁle in this population. Studies have shown an
increase in the incidence of diabetes, hypertension, and dyslipi-
demia, as well as increased risk for the metabolic syndrome, even
after adjustment for confounding variables [2]. Deposition of
abdominal fat is also increased as compared to peripheral fat [3].
Prospective randomized trials have shown that hormone therapy
(HT) is not beneﬁcial for primary or secondary cardiovascular
prevention [4,5]. A recent analysis, however, indicates that HT
may be safe for recently postmenopausal women in whom
atherosclerosis is still not entirely established [6].
Recently, single nucleotide polymorphisms (SNPs) rs9939609 T/
A and rs8050136 A/C of the fat mass and obesity-associated (FTO)
gene have been linked to body mass index (BMI), risk of obesity,
adiposity, metabolic syndrome and high cardiovascular risk in both
men and women. A case–control study from the Women’s Health
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showed an association of polymorphisms rs9939609 and rs8050136
with BMI and waist circumference in white and Hispanic
postmenopausal women, but no association was observed with
obesity-related metabolic traits, including systolic blood pressure,
diastolic blood pressure, plasma fasting insulin, glucose, and ultra
sensitive C reactive protein (us-CRP), a reliable marker of
cardiovascular risk [7]. In turn, we have recently shown an
association of these FTO gene variants with the lipid accumulation
product (LAP) index, which is also a marker of postmenopausal
cardiovascular and metabolic risk [8]. LAP is based on a combination
of two measurements: waist circumference and the fasting
concentration of triglycerides. Studies have shown an association
of LAP with cardiovascular risk factors and metabolic comorbidities
in a healthy population [9,10]. There are, however, no studies in the
literature evaluating whether the presence of FTO gene variants
inﬂuences the effects of HT in postmenopausal women.
Therefore, the aim of the present study was to assess whether
FTO gene polymorphisms rs9939609 T>A and rs8050136 A>C are
associated with changes in anthropometric and metabolic vari-
ables and us-CRP levels in recently postmenopausal women
receiving HT.
2. Materials and methods
2.1. Patients
This randomized crossover study was carried out with women
consulting for climacteric symptoms at the Gynecological Endo-
crinology Unit in a university hospital (Hospital de Clı´nicas de
Porto Alegre) in Brazil. Eighty-six postmenopausal women
fulﬁlling the following inclusion criteria were consecutively
enrolled: last menstrual period between 6 months and 3 years
before the beginning of the study plus follicle-stimulating
hormone levels higher than 35 IU/L; age between 42 and 58
years; no use of any medication known to interfere with hormonal,
glucose, or lipoprotein levels in the past 3 months; no use of
steroidal or nonsteroidal anti-inﬂammatory drugs in the last 15
days. Patients with diabetes, previous hysterectomy, endometrial
thickness >0.5 cm, history of cancer, thromboembolism, or
established cardiovascular disease were excluded [11]. Approval
for this study was obtained from the Institutional Review Board
and the local Ethics Committee, and written informed consent was
obtained from every subject. The study was registered at
clinicaltrials.gov (NCT01432028).
2.2. Study protocol
The sample has been partially described in a previous crossover
randomized study [11] focusing on the effects of low-dose oral HT
and non-oral HT on endothelial function markers and metabolic
variables in early postmenopausal women. Brieﬂy, women were
randomized to receive non-oral HT (3 mg/day intranasal estradiol
daily or 1.5 mg/day transdermal estradiol and 200 mg/day vaginal
micronized progesterone for 14 days/month) or low-dose oral HT
(oral estradiol 1 mg and drospirenone 2 mg/day) for 3 months. Then
the two groups were crossed over without washout for an additional
3 months. In the present study, the correlation between genotype
and us-CRP, anthropometric and metabolic variables was evaluated
before and after 6 months with both forms of HT considered together.
2.3. Anthropometric measurements
Anthropometric measurements included body weight, height,
BMI (current kg/m2) and waist circumference (waist measured at
the midpoint between the lower rib margin and the iliac crest,perpendicularly to the long axis of the body, with the subject
standing balanced on both feet, spread approximately 20 cm apart,
with both arms hanging freely, WC) [12]. Blood pressure was
measured after a 10 min rest. The same calibrated mercury
manometer attached to a 12.5 cm  23 cm inﬂatable cuff was used
in all patients by the same operator. The ﬁfth Korotkoff sound was
adopted to determine diastolic blood pressure [13].
2.4. Laboratory measurements
Blood samples were collected before and after treatment. All
samples were obtained between 08:00 and 10:00 a.m. After a 12-h
overnight fast, blood samples were drawn from an antecubital vein
for determination of lipid proﬁle (total cholesterol, HDL cholesterol
and triglycerides) plasma glucose (oral glucose tolerance test), and
insulin. Blood samples were also drawn for us-CRP. LDL cholesterol
was estimated indirectly with the Friedewald formula [14]. The
LAP index was calculated using the formula [waist (cm) –
58]  triglyceride concentration (mmol/L) [10].
2.5. Biochemical and hormone assays
Total cholesterol, HDL cholesterol and triglycerides were
determined by colorimetric-enzymatic methods (Bayer 1650
Advia System, Deerﬁeld, USA), with intra- and inter-assay
coefﬁcients of variation (CV) <3%. Glucose was determined by
the hexokinase method with intra-assay CV <3.4% and interassay
CV <2.1%. Us-CRP concentrations were measured using a
nephelometric method (Siemens Dade Behring, Deerﬁeld, USA),
with sensitivity of 0.17 mg/L and intra- and inter-assay CV <5%.
Serum insulin levels were determined by electrochemilumines-
cent immunoassays (Roche Diagnostics) with sensitivity of
0.200 mIU/mL, intra-assay CV 2.0% and interassay CV 4.3%.
2.6. Genotyping
In addition to serum samples, whole blood samples were
collected from all women. Genomic DNA was extracted from
peripheral leukocytes following the technique described by Miller
and associates [15]. The DNA samples were diluted to 2 ng/mL and
genotyped for SNP rs9939609 T>A and rs8050136 A>C of the FTO
gene by real-time polymerase chain reaction (7500 Fast Real-Time
polymerase chain reaction Systems, Applied Biosystems, CA, USA),
using the allelic discrimination assay with TaqMan MGB primers
and probes (Applied Biosystems, CA, USA). For a ﬁnal volume of
4 mL per sample, TaqMan Master mix (2.5 mL), TaqMAn assay
(0.250 mL) and H20 (1.250 mL) were added. For a total reaction
volume of 5 mL, 1 mL of DNA was added. Reaction conditions for
the SNP rs9939609 were: 95 8C (10 min) after 50 cycles of
denaturation at 95 8C (15 s) and annealing at 61 8C (1 min).
Reaction conditions for rs8050136 were: 95 8C (10 min) after 40
denaturation cycles at 95 8C (15 s) and annealing at 60 8C (1 min).
Endpoint ﬂuorescent readings were performed by 7500 Fast
System Sequence Detection Software version 1.4.
We calculated Lewontin’s D0 (jD0j) r2 between each pair of
genetic markers for estimating the linkage disequilibrium [16,17].
Haplotypes were constructed from the combination of the two FTO
polymorphisms (rs9939609 and rs8050136), and their frequencies
were inferred using the PHASE 2.1.1 program [18]. The ﬁrst letter of
each haplotype refers to the rs8050136 polymorphism, and the
second to the rs9939609 polymorphism.
2.7. Statistical analysis
Results are expressed as means  SD or medians and inter-
quartile range (25–75%). Analysis of variance for Latin square design
Table 1
Distribution of anthropometric and metabolic variables according the genotype of SNP rs9939609 in postmenopausal women before and 6 months after hormone therapy.
T/T T/A A/A p
Baseline 6 months Baseline 6 months Baseline 6 months
Waist circumference (cm) 84.7  8.2 84.0  8.1 83.3  7.1 81.7  7.3 84.7  5.0 84.0  3.9 0.42
Body mass index (kg/m2) 26.6  2.8 26.4  2.8 25.9  3.4 25.9  3.6 25.8  2.6 25.5  2.2 0.51
Systolic blood pressure (mmHg) 119  13 117  13 117  14 114  14 122  12 114  14 0.41
BP (mmHg) 77  6 76  7 74  8 74  9 78  3 75  7 0.54
Fasting glucose (mg/dL) 93.1  9.2 92.0  7.2 88.7  7.5 89.9  7.85 100.0  18.7 101.3  13.9 0.37
Glucose at 120 min (mg/dL) 102.6  22.4 102.8  29.6 100.5  27.7 110.9  36.2 121.3  36.8 138.3  43.9 0.12
Fasting insulin (mUI/mL) 7.9 (5.8–10.4) 7.2 (5.5–11.8) 5.7 (4.2–8.7) 6.5 (4.7–9.3) 7.0 (6.2–9.4) 6.1 (4.8–7.4) 0.59
Serum cholesterol (mg/dL) 216.0  33.6 193.7  39.4 212.3  27.6 196.9  27.3 230.5  20.0 216.3  47.1 0.74
HDL-c (mg/dL) 63.8  18.6 57.2  16.8 62.5  13.3 58.9  12.0 63.5  10.7 61.2  14.9 0.28
LDL-c (mg/dL) 129.3  31.9 119.6  28.4 125.9  24.9 112.2  26.3 136.2  21.5 129.6  35.3 0.71
Serum triglycerides (mg/dL) 108.8  52.3 115.3  59.4 116.9  51.0 127.6  62.4 153.8  52.3 122.1  44.9 0.05
C reactive protein (mg/L) 1.2 (0.6–2.9) 1.4 (0.4–2.5) 1.5 (0.7–2.8) 2.1 (0.8–3.3) 2.1 (1.1–4.1) 1.2 (0.6–1.8) 0.19
Lipid accumulation product 28.8 (17.4–42.6) 29.5 (18.0–46.9) 29.3 (18.4–43.8) 26.7 (15.4–52.7) 49.9 (31.0–53.6) 32.9 (23.0–46.4) 0.03
Data are mean  SD values median and interquartile range (25–75%) (ANOVA for repeated measures); p = interaction of HT and genotype, i.e. comparisons before and after 6 months
of hormone treatment in each group and between genotype groups.
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and carryover effects. No carryover was observed for any variable.
Non-normally distributed parameters were log10 transformed to
approximate a normal distribution curve before statistical analysis.
Differences between measurements at baseline and at follow-up
were tested with ANOVA for repeated measures. Data were
considered signiﬁcant at P < 0.05.
All analyses were performed using the Statistical Package for
the Social Sciences 18 (SPSS, Chicago, IL, USA).
3. Results
The mean age of participants was 51  3 years. The mean time
since menopause was 22  10 months. Patients were mostly
Caucasian (90.6%), with the remaining participants having mixed
(African and European) descent. While BMI and glucose remained
unchanged after HT, waist circumference, systolic blood pressure,
total cholesterol, HDL-c and LDL-c were reduced after 6 months in the
overall sample (P < 0.05).
Eighty-six patients were genotyped. The frequency of the SNP
rs9939609 was 44.2% for the TT genotype, 40.7% for the TA
genotype, and 10.5% for the AA genotype. The frequency of the SNP
rs8050136 was 13.6% for the AA genotype, 35.8% for the AC
genotype, and 50.6% for the CC genotype. These genotype
frequencies are in agreement with Hardy–Weinberg equilibrium
for both polymorphisms. The rs9939609 polymorphism was in
almost complete linkage disequilibrium with the rs8050136
polymorphism (jD0j = 0953; r2 = 0.876). Five haplotypes were
inferred in this sample (Ht1: CTCT, Ht2: CTCA, Ht3: CTAA, Ht4:
ATAA, Ht5: AAAA). Haplotype frequencies were 46.4% for Ht1,
42.7% for Ht2/Ht3/Ht4, and 10.9% for Ht5.
Table 1 shows the distribution of anthropometric and metabolic
variables according to the genotypes of the SNP rs9939609 in
postmenopausal women before and after HT. Most of the studied
variables remained unchanged after HT, with the exception of LAP,
which were lowered after HT in women with the AA genotype
(P = 0.03).
Table 2 presents the distribution of anthropometric and
metabolic variables according to the genotypes of the SNP
rs8050136 in postmenopausal women before and after HT. No
changes were found among genotypes in the studied variables.
Table 3 shows the distribution of anthropometric and
metabolic variables according to haplotypes. Most of the studied
variables remained unchanged after HT, with the exception of
LAP, which decreased slightly after HT in women presenting
haplotype Ht5.4. Comments
In the present study, FTO gene polymorphisms were not
associated with adverse changes in metabolic variables or us-CRP
levels in response to HT in postmenopausal women. It is important
to note, however, that because of our selection criteria, only women
in the ﬁrst 3 years of the menopause, without clinical evidence of
disease, were included in the study. This may have prevented us
from identifying an association between the investigated SNPs and
altered metabolic variables such as total cholesterol, LDL-c and HDL-
c, which reﬂect a pathologic phenotype.
To the best of our knowledge, this is the ﬁrst study assessing the
relationship between FTO gene polymorphisms and HT. In general,
studies focusing speciﬁcally on the effect of HT in early
postmenopausal women report favorable outcomes. For example,
the Coronary Artery Calcium Study (WHI-CACS) [19], which
included women with age between 50 and 59 years, reported
that beginning HT soon after the menopause contributes to a
reduction in coronary artery calciﬁcation and in the prevalence of
subclinical coronary disease. A reanalysis of WHI data [20] showed
that women starting HT near the menopause also present a
reduction in the risk of developing cardiovascular disease. In
addition, one meta-analysis of randomized clinical trials compar-
ing the results of coronary heart disease after menopausal HT in
young versus older women demonstrated a cardiovascular beneﬁt
of early HT initiation [21].
Our group has also observed that treatment did not affect
variables related to cardiovascular risk in a population of healthy,
early postmenopausal women in a study comparing low-dose oral
HT and nonoral HT [11]. Similarly, in the present study, no changes
were found after HT in the anthropometric and metabolic proﬁle of
postmenopausal women. These observations are supported by
evidence suggesting that HT does not have adverse effects on BMI
[22], blood pressure [23] and vascular function [24].
We observed a strong linkage disequilibrium, consistent with
the ﬁndings of previous studies [25,26], between the two
polymorphisms of the FTO gene. However, even though higher
LAP values were recorded before treatment in women carrying
genotype AA in either SNP or in the Ht 5 haplotype, which contains
both A alleles of the two SNPs, no deleterious LAP changes
occurred after treatment. Concerning the LAP index, results from
the Ludwigshafen risk and cardiovascular health study (LURIC),
which included postmenopausal women at high cardiovascular
risk, have shown a positive association between high LAP and
heart failure mortality in normal weight women [27]. Another
study showed an independent association of LAP levels with
Table 2
Distribution of anthropometric and metabolic variables according to the genotype of SNP rs8050136 in postmenopausal women before and 6 months after hormone therapy.
A/A A/C C/C p
Baseline 6 months Baseline 6 months Baseline 6 months
n (%) 11 (13.6) 11 (13.6) 29 (35.8) 29 (35.8) 41 (50.6) 41 (50.6)
Waist circumference (cm) 82.8  6.2 81.9  5.8 83.6  7.2 82.0  7.5 84.7  7.9 84.0  7.8 0.54
Body mass index (kg/m2) 24.6  3.5 24.4  3.2 26.1  3.2 26.06  3.3 26.7  2.8 26.5  2.86 0.81
Systolic blood pressure (mmHg) 122  12 114  13 116  14 113  15 119  12 117  13 0.48
Diastolic blood pressure (mmHg) 77  4 76  6 74  8 74  9 76  6 76  7 0.95
Fasting Glucose (mg/dL) 97.0  18.2 99.2  13.4 88.4  7.4 89.5  8.1 93.0  8.9 91  7.1 0.23
Glucose at 120 min (mg/dL) 118.2  33.8 134.7  40.2 100.2  30.5 111.8  39.0 102.1  21.6 101.8  28.7 0.07
Fasting insulin (mUI/mL) 7.0 (5.4–9.0) 6.1 (4.7–7.2) 5.7 (4.2–9.1) 6.4 (4.4–9.5) 7.9 (5.8–10.2) 7.2 (5.4–10.3) 0.61
Serum cholesterol (mg/dL) 227.3  19.8 212.0  43.2 211.5  29.8 195.6  29.2 215.6  32.3 195.0  38.4 0.87
HDL-c (mg/dL) 60.4  12.1 58.5  14.8 63.9  13.5 59.7  12.3 64.0  17.9 57.7  16.3 0.35
LDL-c (mg/dL) 136.1  19.9 126.4  32.7 123.8  26.4 109.6  27.8 129.1  30.5 120.6  27.7 0.69
Serum triglycerides (mg/dL) 153.4  47.8 131.1  50.8 116.0  53.1 129.5  63.6 107.2  51.1 111.9  58.2 0.10
C reactive protein (mg/L) 2.1 (1.4–3.3) 1.2 (0.6–1.9) 1.2 (0.6–2.5) 2.1 (0.8–3.4) 1.3 (06–2.9) 1.4 (0.5–2.6) 0.07
Lipid accumulation product 40.9 (26.4–53.6) 32.9 (22.6–43.5) 30.6 (18.2–46.8) 32.7 (15.2–53.1) 27.7 (18.1–42.6) 27.6 (17.9–46.6) 0.10
Data are mean  SD values median and interquartile range (25–75%) (ANOVA for repeated measures); p = interaction of HT and genotype, i.e. comparisons before and after 6 months
of hormone treatment in each group and between genotype groups.
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but not men [28]. This is also in agreement with previous studies
by our group that showed a relationship between LAP and
cardiovascular risk factors [29] as well as with the AA genotypes of
both FTO gene polymorphisms [8].
The mechanism of action of the FTO variant on risk of
metabolic traits and markers of cardiovascular risk remains
uncertain. Recent studies suggest that FTO is a member of the
non-heme superfamily, which encodes 2-oxoglutarate (2-OG)-
dependent dioxygenases [30]. Members of this superfamily are
involved in various cellular processes, including DNA repair,
fatty acid metabolism and post-translational modiﬁcations. The
SNPs rs9939609 and rs8050136 are not likely a causal variant;
SNPs in the ﬁrst intron of the FTO gene are in linkage
disequilibrium with each other and there is not one SNP which
can be treated as tagSNP across all ethnicities [31]. It is unclear
whether these variations inﬂuence FTO expression or splicing or
act as regulatory elements.
Concerning ethnicity, one meta-analysis of studies regarding
the FTO gene and SNPs rs9939609 and rs8050136 provided
signiﬁcant evidence of a modest increase in the risk of obesity in
Caucasian and Asian samples [31]. Another meta-analysis includ-
ing only Asians showed the same polymorphisms associated with
obesity risk in these populations [32]. Nevertheless, ethnic-speciﬁc
associations were not observed between FTO and metabolicTable 3
Distribution of anthropometric and metabolic variables according to the haplotypes of fat
months after hormone therapy.
Ht 1 Ht 2–4
Baseline 6 months Baselin
Waist circumference (cm) 84.7  8.2 84.0  8.1 83.3 
Body mass index (kg/m2) 26.6  2.8 26.4  2.8 25.9 
Systolic blood pressure (mmHg) 119.5  13.0 117.6  13.8 117.0 
Diastolic blood pressure (mmHg) 77  6 76  7 74  8
Fasting glucose (mg/dL) 93.1  9.2 92.0  7.2 88.7 
Glucose at 120 min (mg/dL) 102.6  22.4 102.8  29.6 100.5 
Serum cholesterol (mg/dL) 216  33 193  39 212  2
HDL-c (mg/dL) 63  18 57  16 62  1
LDL-c (mg/dL) 129  31 119  28 125  2
Serum triglycerides (mg/dL) 108  52 115  59 116  5
C reactive protein (mg/L) 1.5 (0.5–2.8) 1.4 (0.4–2.6) 1.7 (
Lipid accumulation product index 28.8 (17.4–42.6) 29.5 (18.0–46.9) 29.3 (
Data are mean  SD values median and interquartile range (25–75%) (ANOVA for repeate
months of hormone treatment in each group and between haplotype groups.variables in a case–control study with postmenopausal women
[7]. Interestingly, a recent meta-analysis has shown that partici-
pants having the FTO risk allele in SNP rs9939609 may have the
odds ratio for obesity attenuated by 27% if they are physically
active [33], suggesting a possible inﬂuence of lifestyle on
phenotype/genotype interactions.
Other FTO gene polymorphisms have been associated with
increased insulin, glucose, cholesterol and triglyceride levels, as
well as with lower HDL-cholesterol levels in several populations
[34,35]. Similarly, a previous study carried out by our group
including most of the participants in the present study found that
the SNP rs9939609 was related to abnormal glucose levels, but not
to other metabolic variables [8]. Further, after adjustment for BMI,
other investigators did not observe an association with insulin,
HOMA-b, glucose and HDL-c [32,36].
In the present study, addressing the impact of FTO gene
polymorphisms on the response to HT, we found no deleterious
inﬂuence of homozygous wild genotype (AA) in the SNP rs8050136
on us-CRP levels after HT in recent postmenopausal women.
Conversely, other studies have associated FTO gene polymor-
phisms with increased levels of CRP and higher cardiovascular risk
in white European [37], and postmenopausal women [8], while
others did not observe this association. Nevertheless, no previous
study has speciﬁcally addressed the inﬂuence of polymorphisms
on the response to HT. mass and obesity-associated gene variants in postmenopausal women before and 6
 Ht 5 p
e 6 months Baseline 6 months
 7.1 81.7  7.3 84.7  5.0 84.0  3.9 0.42
 3.4 25.9  3.6 25.8  2.6 25.5  2.2 0.51
 14.1 114.6  14.1 122.8  114.8 114.8  14.9 0.41
 74  9 78  3 75  7 0.54
 7.5 89.9  7.8 100.0  18.7 101.3  13.9 0.37
 27.7 110.9  36.2 121.3  36.8 138.3  43.9 0.12
7 196  27 230  20 216  47 0.74
3 58  12 63  10 61  14 0.28
4 112  26 136  21 129  35 0.71
1 127  62 153  52 122  44 0.05
0.6–3.3) 2.1 (0.8–3.3) 2.6 (1.0–4.6) 1.2 (0.6–1.8) 0.19
18.4–43.8) 26.7 (15.4–52.7) 49.9 (31.0–53.6) 32.9 (23.0–46.4) 0.03
d measures); p = interaction of HT and haplotype, i.e. comparisons before and after 6
R.B. Ramos et al. / European Journal of Obstetrics & Gynecology and Reproductive Biology 165 (2012) 302–306306Conclusions
The presence of fat mass and obesity-associated gene risk
variants in healthy early postmenopausal women does not
adversely affect their response of to hormone therapy.
Acknowledgements
This work was supported by grants from Conselho Nacional
de Desenvolvimento Cientı´ﬁco e Tecnolo´gico (CNPq INCT
573747/2008-3), Coordenac¸a˜o de Aperfeic¸oamento de Pessoal
de Nı´vel Superior (CAPES 1289/05) and Fundo de Apoio a`
Pesquisa do Hospital de Clı´nicas de Porto Alegre (FIPE-HCPA 340/
2004), Brazil. The funding sources were not involved in study
design; in the collection, analysis and interpretation of data; in
the writing of the report; and in the decision to submit the paper
for publication. Written consent for publication was obtained
from the patients.
References
[1] Mikkola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and
vascular function. Cardiovascular Research 2002;53:605–19.
[2] Derby CA, Crawford SL, Pasternak RC, Sowers M, Sternfeld B, Matthews KA.
Lipid changes during the menopause transition in relation to age and weight:
the study of women’s health across the nation. American Journal of Epidemi-
ology 2009;169:1352–61.
[3] Kanaley JA, Sames C, Swisher L, et al. Abdominal fat distribution in pre- and
postmenopausal women: the impact of physical activity, age, and menopausal
status. Metabolism Clinical and Experimental 2001;50:976–82.
[4] Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for
secondary prevention of coronary heart disease in postmenopausal women.
Heart and Estrogen/Progestin Replacement Study (Hers) Research Group.
JAMA The Journal of the American Medical Association 1998;280:605–13.
[5] Pradhan AD, Manson JE, Rossouw JE, et al. Inﬂammatory biomarkers, hormone
replacement therapy, and incident coronary heart disease: prospective analy-
sis from the Women’s Health Initiative observational study. JAMA The Journal
of the American Medical Association 2002;288:980–7.
[6] Harman SM, Vittinghoff E, Brinton EA, et al. Timing and duration of meno-
pausal hormone treatment may affect cardiovascular outcomes. American
Journal of Medicine 2011;124:199–205.
[7] Song Y, You NC, Hsu YH, et al. FTO polymorphisms are associated with obesity
but not diabetes risk in postmenopausal women. Obesity (Silver Spring)
2008;16:2472–80.
[8] Ramos RB, Casanova GK, Maturana MA, Spritzer PM. Variations in the fat mass
and obesity-associated (FTO) gene are related to glucose levels and higher lipid
accumulation product in postmenopausal women from southern Brazil. Fer-
tility and Sterility 2011;96:974–9.
[9] Taverna MJ, Martinez-Larrad MT, Frechtel GD, Serrano-Rios M. Lipid accumu-
lation product: a powerful marker of metabolic syndrome in healthy popula-
tion. European Journal of Endocrinology/European Federation of Endocrine
Societies 2011;164:559–67.
[10] Kahn HS. The ‘‘lipid accumulation product’’ performs better than the body
mass index for recognizing cardiovascular risk: a population-based compari-
son. BMC Cardiovascular Disorders 2005;5:26.
[11] Casanova G, Radavelli S, Lhullier F, Spritzer PM. Effects of nonoral estradiol–
micronized progesterone or low-dose oral estradiol–drospirenone therapy on
metabolic variables and markers of endothelial function in early postmeno-
pause. Fertility and Sterility 2009;92:605–12.
[12] Toscani M, Migliavacca R, Sisson de Castro JA, Spritzer PM. Estimation of
truncal adiposity using waist circumference or the sum of trunk skinfolds: a
pilot study for insulin resistance screening in hirsute patients with or without
polycystic ovary syndrome. Metabolism Clinical and Experimental 2007;56:
992–7.
[13] Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint
national committee on prevention, detection, evaluation, and treatment of
high blood pressure: the JNC 7 report. JAMA The Journal of the American
Medical Association 2003;289:2560–72.[14] Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of
low-density lipoprotein cholesterol in plasma, without use of the preparative
ultracentrifuge. Clinical Chemistry 1972;18:499–502.
[15] Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting
DNA from human nucleated cells. Nucleic Acids Research 1988;16:1215.
[16] Hedrick PW. Gametic disequilibrium measures: proceed with caution.
Genetics 1987;117:331–41.
[17] Lewontin RC. On measures of gametic disequilibrium. Genetics 1988;120:
849–52.
[18] Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype
reconstruction from population data. American Journal of Human Genetics
2001;68:978–89.
[19] Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronary-
artery calciﬁcation. New England Journal of Medicine 2007;356:2591–602.
[20] Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy
and risk of cardiovascular disease by age and years since menopause. JAMA
The Journal of the American Medical Association 2007;297:1465–77.
[21] Salpeter SR, Cheng J, Thabane L, Buckley NS, Salpeter EE. Bayesian meta-
analysis of hormone therapy and mortality in younger postmenopausal wom-
en. American Journal of Medicine 2009;122. 1016-22 e1.
[22] Norman RJ, Flight IH, Rees MC. Oestrogen and progestogen hormone replace-
ment therapy for peri-menopausal and post-menopausal women: weight
and body fat distribution. Cochrane Database of Systematic Reviews 2000.
CD001018.
[23] Hemelaar M, van der Mooren MJ, van Baal WM, Schalkwijk CG, Kenemans P,
Stehouwer CD. Effects of transdermal and oral postmenopausal hormone
therapy on vascular function: a randomized, placebo-controlled study in
healthy postmenopausal women. Menopause 2005;12:526–35.
[24] Salpeter SR, Walsh JM, Ormiston TM, Greyber E, Buckley NS, Salpeter EE. Meta-
analysis: effect of hormone-replacement therapy on components of the met-
abolic syndrome in postmenopausal women. Diabetes Obesity and Metabo-
lism 2006;8:538–54.
[25] Frayling TM, Timpson NJ, Weedon MN, et al. A common variant in the FTO gene
is associated with body mass index and predisposes to childhood and adult
obesity. Science 2007;316:889–94.
[26] Hotta K, Nakata Y, Matsuo T, et al. Variations in the FTO gene are associated
with severe obesity in the Japanese. Journal of Human Genetics 2008;53:
546–53.
[27] Wehr E, Pilz S, Boehm BO, Marz W, Obermayer-Pietsch B. The lipid accumula-
tion product is associated with increased mortality in normal weight post-
menopausal women. Obesity (Silver Spring) 2011;19:1873–80.
[28] Bozorgmanesh M, Hadaegh F, Azizi F. Predictive performances of lipid accu-
mulation product vs. adiposity measures for cardiovascular diseases and all-
cause mortality, 8.6-year follow-up: Tehran lipid and glucose study. Lipids in
Health and Disease 2010;9:100.
[29] Maturana MA, Moreira RM, Spritzer PM. Lipid accumulation product (LAP) is
related to androgenicity and cardiovascular risk factors in postmenopausal
women. Maturitas 2011;70:395–9.
[30] Gerken T, Girard CA, Tung YC, et al. The obesity-associated FTO gene encodes a
2-oxoglutarate-dependent nucleic acid demethylase. Science 2007;318:
1469–72.
[31] Peng S, Zhu Y, Xu F, Ren X, Li X, Lai M. FTO gene polymorphisms and obesity
risk: a meta-analysis. BMC Medicine 2011;9:71.
[32] Xi B, Mi J. FTO polymorphisms are associated with obesity but not with
diabetes in East Asian populations: a meta-analysis. Biomedical and Environ-
mental Sciences 2009;22:449–57.
[33] Kilpelainen TO, Qi L, Brage S, et al. Physical activity attenuates the inﬂuence of
FTO variants on obesity risk: a meta-analysis of 218,166 adults and 19,268
children. PLoS Medicine 2011;8:e1001116.
[34] Grunnet LG, Brons C, Jacobsen S, et al. Increased recovery rates of phospho-
creatine and inorganic phosphate after isometric contraction in oxidative
muscle ﬁbers and elevated hepatic insulin resistance in homozygous carriers
of the A-allele of FTO rs9939609. Journal of Clinical Endocrinology and
Metabolism 2009;94:596–602.
[35] Hakanen M, Raitakari OT, Lehtimaki T, et al. FTO genotype is associated with
body mass index after the age of seven years but not with energy intake or
leisure-time physical activity. Journal of Clinical Endocrinology and Metabo-
lism 2009;94:1281–7.
[36] Mitchell JA, Church TS, Rankinen T, Earnest CP, Sui X, Blair SN. FTO genotype
and the weight loss beneﬁts of moderate intensity exercise. Obesity (Silver
Spring) 2010;18:641–3.
[37] Ahmad T, Chasman DI, Mora S, et al. The fat-mass and obesity-associated (FTO)
gene, physical activity, and risk of incident cardiovascular events in white
women. American Heart Journal 2010;160:1163–9.
